Robert CPA - OncoSec Medical VP Controller
| ONCSDelisted Stock | USD 0.06 0 3.63% |
Insider
Robert CPA is VP Controller of OncoSec Medical
| Age | 51 |
| Phone | 855 662 6732 |
| Web | https://oncosec.com |
OncoSec Medical Management Efficiency
The company has return on total asset (ROA) of (0.9284) % which means that it has lost $0.9284 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.1017) %, meaning that it created substantial loss on money invested by shareholders. OncoSec Medical's management efficiency ratios could be used to measure how well OncoSec Medical manages its routine affairs as well as how well it operates its assets and liabilities.OncoSec Medical currently holds 6.17 M in liabilities with Debt to Equity (D/E) ratio of 0.76, which is about average as compared to similar companies. OncoSec Medical has a current ratio of 4.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about OncoSec Medical's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Professor MD | Allarity Therapeutics | 67 | |
| JD MBA | Immix Biopharma | N/A | |
| MPA MD | Unicycive Therapeutics | 52 | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| Nandan BS | Immix Biopharma | 63 | |
| Karen Cashmere | ZyVersa Therapeutics | 73 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Jonathan Rothbard | 180 Life Sciences | 71 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Raphael Mechoulam | 180 Life Sciences | N/A | |
| John CPA | Unicycive Therapeutics | 63 | |
| Sharon McBrayer | Palisade Bio | N/A | |
| James Foster | Virax Biolabs Group | 40 | |
| Steen Knudsen | Allarity Therapeutics | 64 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Annie Rasmussen | Allarity Therapeutics | 67 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| DSc MSE | Immix Biopharma | 75 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 61 | |
| Robert McRae | Palisade Bio | N/A | |
| Jason Davis | Virax Biolabs Group | 53 | |
Management Performance
| Return On Equity | -4.1 | |||
| Return On Asset | -0.93 |
OncoSec Medical Leadership Team
Elected by the shareholders, the OncoSec Medical's board of directors comprises two types of representatives: OncoSec Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OncoSec. The board's role is to monitor OncoSec Medical's management team and ensure that shareholders' interests are well served. OncoSec Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OncoSec Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert CPA, VP Controller | ||
| Kim Jaffe, Assistant Operations | ||
| Robert Arch, CEO Pres | ||
| Tu MSc, VP Operations | ||
| CPA CFA, Exec CFO | ||
| Mai MD, Consultant | ||
| Sandra Aung, Sr Officer |
OncoSec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OncoSec Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.1 | |||
| Return On Asset | -0.93 | |||
| Current Valuation | 5.6 M | |||
| Shares Outstanding | 5.96 M | |||
| Shares Owned By Insiders | 28.01 % | |||
| Shares Owned By Institutions | 5.83 % | |||
| Number Of Shares Shorted | 192.06 K | |||
| Price To Earning | (3.12) X | |||
| Price To Book | 0.78 X | |||
| EBITDA | (35.92 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in OncoSec Stock
If you are still planning to invest in OncoSec Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the OncoSec Medical's history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |